TBO-filgrastim

TBO-filgrastim, cool name! Where did we come up with that one?

 

Teva BiOlogics

 

Any word on when product training will happen?

 

no, but this product will revolutionize Oncology...i cannot wait!

wonder what all the people that have left are thinking now?!?!?!?

 

why do you say revolutionize? it's a biosimilar of another drug. I guess no chance of seeing it on the market this year since there is no word on product training.

 

I heard traing was starting after the NFM

 

I am thinking that you will have a "me-too", supportive care drug. You will have a great time negotiating market share contracts and feeling like a used car salesman. Meanwhile, the people who left will be selling drugs that actually bring hope by successfully treating diseases. Why would they possibly regret leaving BC and MS's little shop of horrors?

 

Bio similar you fool! Not a generic! BIG DIFFERENCE...MS said so!!!!!

 

What is NFM?

Biosimilars are doing very well in Europe. I anticipate the US having the same affect. It's about time we get prices down and stop the overcharging of branded products. I am looking forward to the biosimilars hitting the US

 

BB

 

It's so cute watching these yokels try to run an oncology organization. Apparently the new CEO doesn't find much value in them or the "revolutionary" biologics either given the investor presentations. It was a great run but time to move on. Not sure why any of us are surprised after seeing them in action right after joining this train wreck.

 

You are giving Yokels a bad name.

 

LOL!! funny stuff

 

And what are Copaxone, Trisenox, and Treanda? Are they branded?

 

Exactly....the knowledge base there is so bad...they still have some very good reps there especially in the Atlantic and far West....and they all have targets on their back....How long will take the Teva people to figure it out...?

 

It is coming November 2013. You really don't know this? Also, it's not a biosimilar. Ugh...

 

The trademark name for the tbo-filgrastim is Neutroval.

Teva will be market Neutroval using a new Antares Pharma autoinjector, to be announced later this year.

For the biggest bang for the investment buck will be ATRS... since they will also be using an ATRS injector for Copaxone 3TW, to be announced in the March when they file the NDA....

 

All of this means little if there is no pay. Treanda approaching a billion dollars in sales and Oncology reps are capped at 29K bonus with a 20% hold back. What greed and what a joke. They want you to sell a very difficult drug(Synribo) for no bonus, launch GCSF, engage in a lot of work over the next nine months. I know the truth now, should have stayed where I came from. Oncology counterparts are doing very well with their bonuses at other companies, especially those involved in recent product launches. It's by far the worst compensation package in my 7 year Oncology career.

 

BB

 

Great points... A great example in Chicago where a rep with little Oncology experience left and was able to land a good biotech Onc job. Rumor is her offer was such a no brainer, Teva made it easy for her to leave. Why would anyone from Amgen would want to come here? They have a 10 percent match on the 401k, give huge amounts of stock....probably the outcasts. What did they promise them?